Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Weird and nice to see a stock do so well after a reverse split. Up more after hours with a $17 price target added to it Friday.
its a 1-10[color=red][/color]
* * $IDXG Video Chart 12-17-2019 * *
Link to Video - click here to watch the technical chart video
News: $IDXG Interpace Biosciences Announces New Draft LCD and Reimbursement for Its Proprietary Thyroid Assay, ThyGeNEXT®
Parsippany, NJ, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced that its Medicare Administrative Contractor (MAC) has issued a new draft local coverage determination (LCD) for the Company’s ThyGeNEXT ® test, representing an incr...
Got this from IDXG - Interpace Biosciences Announces New Draft LCD and Reimbursement for Its Proprietary Thyroid Assay, ThyGeNEXT®
Between 1 for 5 and 1 for 15
What will the share split be? I looked for the letter but I couldn't find it.
News: $IDXG Interpace Biosciences Launches New Corporate Website
PARSIPPANY, NJ, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (IDXG) announced today that it is launching its new corporate website, “Interpace.com”. Now both the Diagnostics and Pharma Solutions businesses of Interpace are represented together on one easy to n...
Got this from IDXG - Interpace Biosciences Launches New Corporate Website
Okay, thanks. Definitely bad news for current shareholders.
Saw it in the proxy vote I received via email as a shareholder. No announcement, but a vote coming at the next board meeting in December
Where can you find this reverse split announcement?
Announcement of a reverse split will do that...
* * $IDXG Video Chart 11-25-2019 * *
Link to Video - click here to watch the technical chart video
DJ Interpace Diagnostics Initiated at Outperform by Oppenheimer
DJ Interpace Diagnostics Price Target Announced at $3.00/Share by Oppenheimer
Thu Sep 26 06:46:37 2019 EDT
Expansion ,expansion=$$$$$$$$$$$, load more and hold
News: $IDXG Interpace to Present at the 21st Annual Global Investment Conference Sponsored by H.C. Wainwright
PARSIPPANY, NJ, Sept. 06, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (“Interpace” or the “Company”) (NASDAQ: IDXG) today announced that the Company will present at the upcoming 21 st Annual Global Investment Conference, sponsored by H.C. ...
Find out more IDXG - Interpace to Present at the 21st Annual Global Investment Conference Sponsored by H.C. Wainwright
News: $IDXG Interpace Announces New Agreement with SelectHealth
Expected to Benefit More than 850,000 Members PARSIPPANY, NJ, July 22, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it has reached an agreement with SelectHealth (a plan associated with Intermountain Healthcare) to provide its propriet...
In case you are interested Interpace Announces New Agreement with SelectHealth
News: $IDXG Interpace Diagnostics Enters Agreement with Predictive Oncology to Enhance Diagnosis of Thyroid Cancer Via AI-Driven Analysis
PARSIPPANY, NJ, July 18, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) (“Interpace” or the “Company), announced today that it has executed an agreement with the Helomics division of Predictive Oncology (NASDAQ: POAI), a company focused on app...
Got this from Interpace Diagnostics Enters Agreement with Predictive Oncology to Enhance Diagnosis of Thyroid Cancer Via AI-Driven Analysis
Yea lunch time dump i with that $$$
I want to see how it does in a few minutes when the market opens around 11a.m I will be looking to Short
The bankruptcy is what is the worry but the hand off to the other company bring promising results i think thats why its going nuts right now
Im not at the moment but may toward the end of day.
LGCY ?? Do you plan to short this one??
Looking at lgcy moving crazy up about 300 bucks already ill look into to that marked you
Add KPAY to your watch list..
When I looked at the stock in the premarket.. the O/S was a bit to large and there wasn't enough shorts or volume for this stock to shoot up.. I figured it would at least make it in to the high 90's and max out on thin volume at $1.08 but it ran out of gas pretty quick
Well fast when your right your right not looking good I was hoping for your 1.05 prediction to be right but I guess we are both wrong.
* * $IDXG Video Chart 06-20-2019 * *
Link to Video - click here to watch the technical chart video
After market run with a pre market run $$$
Lunch was great dinner will be better!! $$$
What time should I check back LOL.... LIKE I said it's not going to be a big mover
Lol its not even 11 yet. $$$
Told you it wouldn't go to far..
News: $IDXG Interpace Diagnostics Announces Coverage of Molecular Thyroid Testing by Independence Blue Cross
PARSIPPANY NJ, June 20, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that its ThyGeNEXT™ and ThyraMIR ® tests for thyroid cancer are now covered by Independence Blue Cross (Independence), providing plan benefits coverage for its memb...
Read the whole news https://marketwirenews.com/news-releases/interpace-diagnostics-announces-coverage-of-molecular-thyroid-testing-by-independence-blue-cross-8387984.html
Could get much higher
This tops out at a max of $1.08 if your lucky... Take a screenshot of this post
Jumping in on this puppy looking great pre market $$$
Agreed, would like it to come back down though. No gap n trap.
Interpace Diagnostics Announces Presentation at the World Congress on Thyroid Cancer
Source: GlobeNewswire Inc.?
Interpace Diagnostics Group, Inc. (NASDAQ: IDXG), a fully integrated bioinformatics and commercial molecular diagnostic company, today announced that Dr. Sydney D. Finkelstein, Interpace’s Chief Scientific Officer, will present at the World Congress on Thyroid Cancer, which is being held in Rome, Italy from June 20-22, 2019. The presentation will detail outcomes of a study with patients using Interpace’s ThyGenX® and ThyGeNEXT® in combination with microRNA (miRNA) testing in indeterminate thyroid nodules.
Session Information:
Presentation Title: Incremental value of expanded mutation panel when used in combination with microRNA testing in indeterminate thyroid nodules
Date: June 21, 2019
Time: 1:30 pm - 3:15 pm
Room: Orsini, Level A
“I am excited to present findings from Interpace’s thyroid study at the World Congress on Thyroid Cancer,” stated Dr. Sydney D. Finkelstein, Interpace’s Chief Scientific Officer. “Based on the number of participating patients, we believe this is one of the largest and most comprehensive studies of its kind. The trial evaluated over 8,000 patients and resulted in important learnings for the field of analyzing thyroid nodules and diagnosing thyroid cancer.”
The World Congress on Thyroid Cancer event is expected to consist of more than 150 faculty and 500 delegates, including leaders in the field of thyroid nodules and thyroid cancer as well as Endocrinologists, Surgeons, Oncologists, Radiologists and Nuclear Medicine Specialists. Interpace’s presentation will be held during a non CME accreditation session.
About Interpace Diagnostics Group
Interpace is a fully integrated commercial and bioinformatics company that provides clinically useful molecular diagnostic tests and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace’s mission is to provide personalized medicine through molecular diagnostics, innovation and data to advance patient care based on rigorous science. The Company currently has four commercialized molecular tests and one test in a clinical evaluation process (CEP); PancraGEN® for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGeNEXT® (previously ThyGenX®) for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; ThyraMIR® for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay; and RespriDx® that differentiates lung cancer of primary vs. metastatic origin. BarreGEN® for Barrett's Esophagus, is currently in a Clinical Evaluation Program whereby we gather information from physicians using BarreGEN® to assist us in positioning the product for full launch, partnering and potentially supporting reimbursement with payers. Barrett's Esophagus is a rapidly growing diagnosis that affects over three million people in the US and over time can progress to esophageal cancer. The Company’s data base includes data from over 50,000 patients who have been tested using the Company’s current products, including over 25,000 molecular tests for thyroid nodules. Interpace has been designated by the 2018 edition of CIO Applications as one of the top 10 companies for providing bioinformatics solutions. Interpace’s mission is to provide personalized medicine through molecular diagnostics, innovation and data to advance patient care based on rigorous science. For more information, please visit Interpace’s website at www.interpacediagnostics.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Company’s future financial and operating performance. The Company has attempted to identify forward looking statements by terminology including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company’s control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to be materially different from those expressed or implied by any forward-looking statement. Additionally, all forward-looking statements are subject to the “Risk Factors” detailed from time to time in the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other SEC filings. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
CONTACTS:
Investor Relations
Joseph Green
Edison Group
jgreen@edisongroup.com
?
?
News: $IDXG Interpace Diagnostics Announces New York State Approval
State of New York Approves Commercialization of ThyraMIR ® Now in Three Specimens PARSIPPANY, NJ, April 23, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) announced today that it has received approval to launch ThyraMIR® diagnostic testing on forma...
Read the whole news https://marketwirenews.com/news-releases/interpace-diagnostics-announces-new-york-state-approval-8041392.html
NOT what i was expecting this am
snuck out, too- with a free steak dinner or two captured-----this one is too scary for the likes ofme to stay in with no real "story". glta
hah!! aren’t you the sneaky one
that was me sneaking in, janey...You had the touch in crmd, janey. So i went and bought me some AH cheapies for my fun playing.....(drum roll please...)...LARK SHARES FOR FREE STEAK DINNERS ONLY. -------Today might be fun.
somebody took some supercheapies in AH - wish it was me
No clue there was nothing bad just didnt hit street numbers on rev but super growth, puzzled have to buy more if it sits below
90 tomm
giant WTF after hours
Followers
|
74
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2812
|
Created
|
02/10/16
|
Type
|
Free
|
Moderators |
Authorized Shares: 20,000,000 shares
Outstanding shares: 8,788,604 - May 05, 2017
Short interest:
64% of Float
Interpace Diagnostics (IDX) was formerly part of PDI that had both IDX and Commercial Services (CSO) businesses. PDI was renamed Interpace Diagnostics Group after the sale of CSO in December 2015
•Focused on developing and marketing molecular based diagnostic tests in high value precision pre-cancerous test markets
•Three proprietary cancer molecular tests on the market in GI and Endocrine
•PancraGenTM–The new standard of pancreatic cyst diagnostics
•ThyGenXTMand ThyraMIRTM-Next-Gen sequencing oncogene panel and miRNAclassifier in combination to improve risk classification of Thyroid nodules
•Two state of the art CLIA-certified labs
•Additional pipeline tests under development including BarreGenTMfor Barrett’s Esophagus, an esophageal cancer risk classifier
•Addressable potential market opportunity of $2.7 billion with all four tests
•Revenue of approximately $10 million in 2015, supported by IDX sales forces
•Focus for 2016: Grow recently launched ThyGenX/ThyraMIRtests and expand PancraGenmarket penetration
Key Milestones:
AUGUST2014:Acquired ThyroidAssetsfrom Asuragen
OCTOBER2014: Acquired RedPathInc., GI assetsand CLIA lab
DECEMBER2014: Launched ThyGenX™NextGen Sequencing Thyroid Cancer Test
FEBRUARY2015: Published landmark study on PancraGen™in Endoscopy
APRIL2015: Launched ThyraMIR™microRNA Gene Expression Thyroid Cancer Test
MAY2015: Published the major clinical validation study in JCEM for combining ThyGenXand ThyraMIRin a single testing service
MAY2015: Published BarreGen™BASE study on Barrett’s Esophagus cancer risk progression in AJG
AUGUST2015: Covered lives for Interpace Diagnostics products exceeded 100 million for all tests combined
OCTOBER2015: Data presented at ACG demonstrate that PancraGen™can improve detection of malignant or highly aggressive pancreatic cysts over current guidelines criteria, and improve patient outcomes in real life management decisions
New data presented at ATA further validates the power of combination testing by ThyGenX™and ThyraMIR™, improving the preoperative diagnosis of thyroid nodules with indeterminate cytology
DECEMBER2015: PDI transformed into Interpace Diagnostics Group through the sale of its CSO business to focus exclusively on molecular diagnostics
High Value Molecular Pre-Cancerous Test Market:
Management Team:
Jack Stover, Interim President and CEO
Mr. Stover has been Chief Executive Officer of Zebec Therapeutics LLC (“Zebec”) since April 2014. Zebec is the successor to Quadrant Pharmaceuticals LLC, which Mr. Stover co-founded and was President and Director of from September 2013. Mr. Stover has been a Director and Chairman of the Audit Committee of PDI, Inc., a public company since 2005. From 2009 to February 2012, Mr. Stover served as the executive chairman of Targeted Nano Therapeutics LLC, a privately held biotechnology company focused on targeted delivery of peptides and proteins. Mr. Stover was also chairman of the audit committee and a member of the board of directors of Arbios Systems Inc. from 2005 to 2008 and a member of the board of directors of Influmedix, Inc. from 2010 to 2011.
From 2004 to 2008, he served as chief executive officer, president and director of Antares Pharma, Inc., a publicly held specialty pharmaceutical company listed on the American Stock Exchange. Prior to that, Mr. Stover was executive vice president and chief financial officer of Sicor, Inc., a publicly held company which manufactured and marketed injectable pharmaceutical products, and which was acquired by Teva Pharmaceutical Industries. Prior to that, Mr. Stover was executive vice president and director of a proprietary women’s pharmaceutical company, Gynetics, Inc. (“Gynetics”), and before Gynetics, he was senior vice president and director of B. Braun Medical, Inc., a private global medical device and pharmaceutical company. For more than five years prior to that, Mr. Stover was a partner with PricewaterhouseCoopers (then Coopers and Lybrand), working in the lifesciences industry division. Mr. Stover received his B.A. in Accounting from Lehigh University and is a Certified Public Accountant.
Greg Richard, SVP Commercial Services
Greg Richard, Sr. Vice President of PDI, Inc. and SVP of Commercial Services at Interpace Diagnostics, has been in the healthcare business for over 25 years in various industries including managed care, biotech pharmaceuticals, CRO services, and diagnostics. He started his career in sales at Aetna and moved to Genentech as the Director of Managed Care. He transitioned in to the diagnostics industry as the Vice President of Managed Care for Quest Diagnostics and served in this role for 8 years. Greg also led the international clinical trials sales team while at Quest. Following his tenure at Quest, Greg worked for several privately held companies including CRO’s, molecular diagnostics, and anatomic pathology services providers. He also served as the Sr. Vice President of Sales for the Northeast Division of LabCorp. Greg is a certified Six Sigma Green Belt and frequent speaker at healthcare industry conferences such as the G2 Lab Institute and the NextGen Dx Summit.
Syd Finkelstein, Chief Scientific Officer
Dr. Finkelstein is a board certified pathologist specializing in gastrointestinal pathology with extensive experience in molecular diagnostics. He is the Adjunct Professor of Pathology, Drexel University on the faculty of Allegheny General Hospital, Pittsburgh, PA. He serves as Adjunct Professor at Temple University. He is the founder of RedPath Integrated Pathology, which was acquired by Interpace Diagnostics in 2014. In this position, Dr. Finkelstein is applying clinical translational research of molecular genetic discoveries to standard surgical pathology practice a goal to which he has dedicated his entire career. He spent 20 years as a practicing academic surgical pathologist, holding appointments as associate and then full professor at the University of Pittsburgh and at Hahnemann University in Philadelphia. In 1990, he began work on the development of Topographic Genotyping, his patented technology for enhancing polymerase chain reaction amplifiability of minute, microdissected, fixative treated tissue samples. Dr. Finkelstein is a nationally recognized expert in both Gastrointestinal Pathology and Solid Tissue Molecular Pathology.
https://www.doximity.com/pub/sydney-finkelstein-md?show_more=true#publications
James E. Early, Interim CFO
Mr. Early, age 62, previously served as the Interim and subsequently permanent Chief Financial Officer of AbGenomics International Inc., a clinical stage drug development company with a product pipeline in immunology and oncology, from September 2015 to July 2016. Mr. Early also previously served as the Chief Financial Officer of Zebec Therapeutics, LLC from October 2014 to September 2015. In addition, Mr. Early has provided interim chief financial officer and business development services for pharmaceutical, life science and other similar companies as a sole proprietor from August 2009 to December 2013 and through Early Financial Consulting, LLC from January 2014 to the present. Mr. Early is a Certified Public Accountant and has an MBA in Finance and Accounting.
http://www.earlycfo.com/
Summary of Early's CFO services:
Key Points:
http://www.ascopost.com/News/29620
PancraGEN® is a unique, DNA-based pancreatic cyst molecular test that, by using a small sample of pancreatic cyst fluid, can aid in pancreatic cancer risk assessment. PancraGEN® is 90% accurate, according to clinical studies, enabling effective risk stratification of patients. Pancreatic cancer is often difficult to diagnose in early stages and typically spreads rapidly with signs and symptoms appearing when the cancer is significantly advanced. Because of this, and that complete surgical removal of the pancreas is not possible, pancreatic cancer is considered a leading cause of cancer deaths.
Long-term follow-up outcomes data of patients (up to 8 years) from the National Pancreatic Cyst Registry supports PancraGEN’s ability to help accurately inform surgery and surveillance decisions of patients.
In a study of the National Pancreatic Cyst Registry, PancraGEN’s recommendation of surveillance was correct in 97% of patients. In fact, PancraGEN diagnoses were more beneficial to overall patient outcomes than sole reliance on International Consensus Guidelines (ICG) criteria.
PancraGEN has been performed on over 25,000 patients with pancreatic cysts, representing a full spectrum of pancreatic cyst patients with diverse clinical and molecular findings.
Medical Publications proving benefits of PancraGen:
http://www.interpacediagnostics.com/pancragen/publications/
ThyGenX® Thyroid Oncogene Panel and ThyraMIR™ Thyroid miRNA Classifier molecular testing that aids in the diagnosis of thyroid nodules by identifying genetic alterations associated with thyroid cancer. ThyGenX® and ThyraMIR™ combination testing helps to better assess the risk of thyroid nodules being either benign or malignant—and helps reduce unnecessary surgeries.
ThyGenX® is a highly specific oncogene (mutational) panel that assesses the most common genetic alterations across 8 genes associated with papillary carcinoma and follicular carcinoma.
ThyraMIR™ is the first and only miRNA gene expression classifier, and is based on evaluation of expression of 10 miRNAs.
AccuCEA is our highly accurate CEA method designed specifically for pancreatic cyst fluids and is especially convenient when used with PancraGEN. Interpace currently performs over 6,000 AccuCEA tests per year for their customers. CEA is a blood fluid chemistry test that is commonly done as part of an initial screening performed on patients suspected of having pancreatic and other types of cancer.
The first of the two posters entitled "Molecular Analysis of Thyroid Malignancy Using Cytology Smears by Combined THYGENX™ and THYRAMIR™ testing: A Prospective Study" highlights the clinical performance of the combined ThyGenX + ThyraMIR tests when carried out on Fine Needle Aspirate (FNA) material smeared on cytology slides.
The second poster entitled "The Majority of Non-Diagnostic (Insufficient) Thyroid Nodule Cytology Samples Can Effectively Undergo Molecular (Combined Mutational and MicroRNA Classifier) Analysis Using a Needle Aspiration Approach" demonstrates that Interpace's scientists were able to perform molecular analysis in cases where cytology results were insufficient.
Set for presentation of posters 50 and 51 on Sept 23:
http://online.liebertpub.com/doi/full/10.1089/thy.2016.29027.abstracts
"DNA Analysis of Pancreatic Cystic Lesions Has Value in Assessing Risk of Future Malignancy"
Oct 19, presented by:
"We are attending the ACG mtg. in Oct. in Las Vegas, where data on our PancraGen test is being presented in a podium presentation by Dr. James Farrell of Yale. " Greg Richard (email 9-21-16)
Lab Locations
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |